During 2021, the project PARITY (Prophylactic Antibiotic Regimens in Tumor Surgery), an international multicenter randomised study, was finalised. The Musculoskeletal Tissue Engineering research group participated as a Spanish national reference and European legal representative. Furthermore, the group was involved as well in the preclinical project of tissue engineered product with mesenchymal stromal cells derived from Wharton's jelly (FIS-2019), which has been completed.
Additionally, a collaboration between the research group, the Laboratori de Desenvolupament de Terapia Cellular and the global healthcare company Grifols has been established. The purpose of the project is to study and evaluate a tissue engineered product in an adult ovine model of cylindrical bone defects. Lastly, a new prospective cohort study has been designed to determine the clinical regeneration using fragmented autologous cartilage in the treatment of grade III-IV focal chondral lesions of the knee.

Group Leader
Roberto Vélez Villa

Principal Investigator (PI)
Joaquim Vives Armengol

Raquel Cabrera Pérez, Nayana Joshi Jubert, Daniel Alejandro Pacha Vicente, Joan Albert Prat Matifoll, Anna Server Salvà

Nursing and Technical Staff
Ángela Roig Molina








Ghert M, Schneider P, Guyatt G, Thabane L, Velez R, et al.
Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial.
JAMA Oncology. 2022 Jan 6. pii: 2787950.
DOI: doi: 10.1001/jamaoncol.2021.6628.
IF: 31.777

Joshi, N., Pujol, O., & Prat, S.
Complex distal femoral fractures in the fragile elderly patient treated by distal femoral replacement: A report of three cases.
Revista Española de Cirugía Ortopédica y Traumatología. 2021 Nov 18.
DOI: https://doi.org/10.1016/j.recot.2021.07.005.

Munoz-Dominguez N, Roura S, Prat-Vidal C, Vives J.
Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View.
Pharmaceutics. 2021 Aug 26;13(9).
DOI: DOI: 10.3390/pharmaceutics13091336.
IF: 6.321

Corona PS, Altayo M, Amat C, Vicente M, Velez R.
Reconstruction of infected post-traumatic bone defects of the distal femur with the Compress() implant. Preliminary results of a staged non-biological strategy.
Injury-International Journal of the Care of the Injured. 2021 Mar;52(3):606-615.
DOI: DOI: 10.1016/j.injury.2020.10.016
IF: 2.586

Albu S, Kumru H, Coll R, Vives J, Valles M, Benito-Penalva J, Rodriguez L, Codinach M, Hernandez J, Navarro X, Vidal J.
Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study.
Cytotherapy. 2021 Feb;23(2):146-156.
DOI: DOI: 10.1016/j.jcyt.2020.08.008
IF: 5.414

Translation of an allogenic tissue engineering product with mesenchymal stromal cells from Wharton’s jelly for the treatment of osteonecrosis in paediatric oncology patients
Principal Investigator: Joaquim Vives Armengol and Roberto Vélez Villa (CO-IP)
Agency: Institut de Salud Carlos III
Funding: 87.120€
Period: 2020-2022

Fibrin Sealant Grifols as scaffold in advanced therapies. 3D printing scaffolds for advanced orthopedic applications. In vivo study.
Principal Investigator: Roberto Vélez Villa and Raquel Cabrera Pérez
Agency: Grifols Worlwide Operations Ltd
Funding: 157.452,18€
Period: 2021-2023

Treatment of grade III-IV chondral focal lesions of the knee with Fragmented Autologous Cartilage (PAC)
Principal Investigator: Nayana Joshi Jubert
Agency: Sociedad Española de la Rodilla
Funding: 10.000€
Period: 2021-2023